Abstracts tagged "prevention"

Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Emilie Stavnsbjerg Larsen¹, Anna Christine Nilsson², Ulrik Stenz Justesen¹, Anne Voss³ and Isik Somuncu Johansen⁴, ¹Odense University Hospital, Odense C, Denmark, ²Odense Universitets Hospital, Odense C, Denmark, ³Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁴Odense University Hospital, Odense, Denmark
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
Abstract Number: 0957 • ACR Convergence 2021
Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial
Jill Hahn¹, Nancy Cook², Erik Alexander³, Sonia Friedman³, Vadim Bubes³, Joseph Walter³, Gregory Kotler³, I-Min Lee³, JoAnn Manson³ and Karen Costenbader⁴, ¹Harvard T.H. Chan School of Public Health, Boston, MA, ²Brigham and Womens' Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA
Background/Purpose: In observational studies, vitamin D has been inconsistently associated with reduced risk of several autoimmune diseases, and a large randomized, controlled trial has been…
Abstract Number: 1077 • ACR Convergence 2021
Effectiveness of Non-Pharmacological Interventions to Promote Work Participation of People with Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Regression Analysis
Maarten Butink¹, Casper Webers², Suzanne Verstappen³, Robin Christensen⁴, Louise Falzon⁵, Johannes Bijlsma⁶, Gerd Burmester⁷ and Annelies Boonen², ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+); Department of Social Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht, Limburg, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, ³School of Social Sciences, The University of Manchester, Manchester, United Kingdom, ⁴Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ⁵Center for Personalized Health, Northwell Health, New York City, NY, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Despite improvements in the treatment of rheumatic and musculoskeletal diseases (RMDs), reduced work participation persists when compared to the general population. A Task Force…
Abstract Number: 1139 • ACR Convergence 2021
Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Muntarin Karim¹, lorien ahn², Jordan Thompson¹, Christina Downey³, Lorena Salto⁴ and Karina Torralba⁵, ¹Loma Linda University, Redlands, CA, ²loma linda university medical center, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University Health, Loma Linda, CA, ⁵Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA
Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
Abstract Number: 1554 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
Valeria Valerio¹, Emmanouil Rampakakis², Marie Hudson³, Sasha Bernatsky³, Elizabeth M. Hazel³ and Ines Colmegna⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²JSS Medical Research, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Vaccination is fundamental to reduce COVID-19 risk and its complications. Vaccine hesitancy is a threat to COVID-19 vaccination uptake. We assessed the frequency of…
Abstract Number: 1557 • ACR Convergence 2021
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
Ana Medeiros-Ribeiro¹, Nadia Aikawa¹, Carla Gonçalves Schahin Saad¹, Emily Figueiredo Vieira Neves Yuki¹, Tatiana do Nascimento Pedrosa¹, Solange Fusco¹, Priscila Rojo¹, Rosa Pereira¹, Samuel Shinjo¹, Danieli Andrade¹, Percival Sampaio-Barros¹, Carolina Ribeiro¹, Giordano Deveza¹, Victor Adriano de Oliveira Martins¹, Clovis Artur Silva¹, Marta Lopes¹, Alberto Duarte¹, Leila Antonangelo¹, Ester Sabino¹, Esper Kallas¹, Sandra Gofinet Pasoto² and Eloisa Bonfá¹, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Hospital das Clinicas de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Brazil is among the countries with the highest numbers of confirmed cases and deaths by COVID-19. CoronaVac (SARS-CoV-2 inactivated vaccine) has been largely used…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 1711 • ACR Convergence 2021
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia risk…
Abstract Number: 1725 • ACR Convergence 2021
Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with SLE are at substantial risk of preeclampsia. Best international practice guidelines recommend aspirin (ASA) in this population, as it reduces preeclampsia…
Abstract Number: 1896 • ACR Convergence 2021
Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
Anna Montgomery¹, Gary Tarasovsky², Iziegbe Ehiorobo³, Mary Whooley², Jennifer Barton⁴, Khushboo Sheth⁵, Kimberly Reiter⁶, Meredith Keller⁷, Lorinda Chung⁸, Lori Bennett⁹, Jo Dana², Elizabeth Wahl¹⁰ and Gabriela Schmajuk³, ¹Department of Veterans Affairs, Tiburon, CA, ²San Francisco VA Healthcare System, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, ⁴Portland VA Healthcare System, Portland, OR, ⁵Stanford University/VA Palo Alto, Atherton, CA, ⁶Raymond G Murphy VA Medical Center, Albuquerque, NM, ⁷New Mexico VA Health Care System, Albuquerque, NM, ⁸Stanford University, Palo Alto, CA, ⁹Charleston VAHCS, Charleston, SC, ¹⁰VA Puget Sound Health Care System, Seattle, WA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for patients with lupus erythematosus, rheumatoid arthritis, and other autoimmune conditions. However, HCQ daily doses of ≥…
Abstract Number: 0091 • ACR Convergence 2021
Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort
Ioana Andreica, Iulia Roman, Xenofon Baraliakos, Juergen Braun and Uta Kiltz, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) are often not adequately protected against infectious diseases. As shown in an earlier study, less than…
Abstract Number: 0100 • ACR Convergence 2021
Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Jutta Richter⁵, Anne Regierer⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Ulf Müller-Ladner¹² and Christof Specker¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁶German Rheumatism Research Center, Berlin, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ¹³Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Among patients with rheumatic and musculoskeletal diseases (RMDs) and their treating physicians, concerns prevail about the effectiveness and safety of vaccination against COVID-19, especially…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].